The Q·Score Snapshot
LLY scores 8 out of 10, carrying a "Bullish" label in the Quantify.biz Q·Score system. The Q·Score is a composite signal drawn from fundamentals, growth metrics, analyst sentiment, and valuation data — a score of 8 reflects that the overwhelming majority of those inputs are pointing in a positive direction. It is a measure of data alignment, not a directive.
Business at a Glance
Eli Lilly is a global pharmaceutical giant headquartered in Indianapolis, operating squarely in the Healthcare sector. The company develops and manufactures treatments across diabetes, oncology, immunology, and neuroscience — with its GLP-1 receptor agonist drugs (used in diabetes management and weight loss) now serving as the primary engine behind its explosive recent growth. With a market capitalisation of approximately $980 billion, Lilly ranks among the largest companies on U.S. exchanges by any measure.
The Numbers That Stand Out
Revenue grew 55.5% year-over-year, an extraordinary rate for a company of this scale, reflecting surging demand for its GLP-1 portfolio including tirzepatide-based therapies. Earnings growth came in at 169.9%, suggesting that revenue is flowing through to the bottom line with significant operating leverage. The profit margin of 35% means Lilly keeps 35 cents of every revenue dollar as net income — a level more commonly associated with software businesses than drug manufacturers. The return on equity of 107.5% (net income divided by shareholders' equity) indicates the company is generating exceptional returns on the capital its shareholders have invested. Perhaps most striking is the 100% EPS beat rate — Lilly has exceeded analyst earnings-per-share estimates in every measured reporting period in the dataset, a streak that speaks to consistent execution relative to expectations.
What Analysts Think
Of the 29 analysts currently covering LLY, 77% carry a positive rating on the stock — indicating a clear lean toward the bullish side of the ledger, though a meaningful minority hold neutral or negative views. The consensus price target implies approximately 10.7% upside from the current price of $1,098.57, with the analyst-derived target sitting in the vicinity of $1,216. That gap suggests the analyst community, in aggregate, sees room between where the stock trades today and where they model fair value — though individual targets vary widely across the coverage universe.
The Bigger Picture
Within the Healthcare sector, Eli Lilly has become something of a category unto itself — its growth rates are running at multiples of what most large-cap pharmaceutical peers are producing, driven almost entirely by the GLP-1 obesity and diabetes wave that has reshaped the industry's competitive landscape. The forward P/E of 24.7x (the stock price divided by expected earnings per share over the next twelve months) is notably moderate relative to the growth rates on display, a data point that analysts and investors frequently flag when discussing the stock's valuation profile. Whether that dynamic persists depends heavily on pipeline execution, manufacturing capacity, and the competitive response from peers — all variables the numbers alone cannot resolve.